Working with Co-Occurring Disorders

A co-occurring disorder — also called dual diagnosis or comorbidity — refers to the presence of at least one mental health disorder and at least one substance use disorder (SUD)in the same person. The two conditions interact, influence each other's course, and often complicate each other's treatment. This is not an unusual presentation to be referred out; for most behavioral health clinicians it is the everyday reality of the caseload.

A common instinct is to ask which disorder came first, as though the "primary" condition were the real problem and the other merely its consequence. In practice the relationship is bidirectional and complex, and several pathways can operate at once:

• Self-medication — a person uses substances to dampen anxiety, quiet intrusive memories, lift depression, or manage insomnia, and use escalates into a disorder of its own.
• Shared risk factors — genetics, early adversity and trauma, chronic stress, and overlapping brain circuits (particularly reward and stress systems) raise the risk of both conditions.
• Substance-induced symptoms — intoxication and withdrawal can produce or amplify depression, anxiety, or psychosis, blurring the line between an independent disorder and a substance-induced one.

Because these pathways overlap, assuming a single direction of causation can lead care astray. The more useful clinical stance is to treat both conditions as real, current, and worthy of attention at the same time.

For decades, mental health and addiction services grew up in separate systems — different funding streams, different training, different buildings. That history produced two treatment models that consistently failed people with co-occurring disorders.

• Sequential treatment asked clients to resolve one condition before the other could be addressed — for example, requiring sobriety before mental health treatment would begin. People with active, interacting disorders were effectively told to fix themselves before they could get help.
• Parallel treatment addressed both conditions at once but in separate, siloed programsthat rarely communicated. The client was left to reconcile conflicting messages, coordinate their own care, and shuttle between systems that each treated the other's focus as someone else's job.

Integrated treatment resolves this by having the same clinician or teamaddress the mental health and substance use conditions together, within one coherent plan. There is one set of appointments, one relationship, and one message: both conditions matter and both are being treated. Decades of research — and SAMHSA's guidance — establish integrated care as the evidence-based standard for this population.

Because co-occurrence is so common, the safest working assumption is that any client may have both. Screening should therefore run in both directions: screen mental health clients for substance use, and screen substance use clients for mental health conditions. A client who presents for depression but is never asked about drinking, and a client in SUD treatment whose untreated PTSD keeps driving relapse, are two versions of the same missed opportunity.

Practical screening tools

Brief, validated instruments make two-directional screening feasible in routine practice:

• AUDIT-C — a three-item screen for hazardous or harmful alcohol use.
• DAST — the Drug Abuse Screening Test, for problematic drug use.
• PHQ-9 and GAD-7 — for depression and anxiety severity in clients presenting primarily for substance use.

Distinguishing substance-induced from independent disorders

One of the central assessment challenges is telling apart a substance-induced disorder from an independent one that co-occurs. Symptoms of depression, anxiety, and even psychosis can be driven by intoxication or withdrawal and may resolve as the substance clears. A period of abstinence and careful observation — where clinically feasible — helps clarify what remains once acute substance effects subside. Assessment is best treated as ongoing rather than a single intake event, with the formulation revised as more information emerges.

Integrated care is not a single technique but a way of organizing treatment around the client's current readiness and needs. Two frameworks anchor the work: stage-wise treatment and motivational interviewing.

Stage-wise treatment

Osher and Kofoed described treatment as moving through predictable stages, each calling for a different clinical focus. Matching your interventions to the client's stage — rather than pushing everyone toward the same goal — keeps people engaged and reduces dropout.

• Engagement — building a trusting working relationship before anything else.
• Persuasion — helping the client recognize how substance use affects their goals and building motivation to change.
• Active treatment — working directly on reducing use and managing the mental health condition.
• Relapse prevention — consolidating gains and extending recovery into other areas of life.

Motivation, harm reduction, and skills

Motivational interviewing (MI) is well suited to this population because it builds internal motivation without confrontation, meeting ambivalence with curiosity rather than pressure. Harm reduction is a valid, evidence-based stance: reducing the risks associated with use — overdose, infection, injury — is worthwhile in its own right and keeps people connected to care even when abstinence is not yet the goal. On the skills side, combining CBT and DBT skills (distress tolerance, emotion regulation, cognitive restructuring) with structured relapse prevention gives clients concrete tools for both conditions. Medication for the mental health disorder should be considered alongside — and coordinated with — any medication for addiction.

For opioid use disorder in particular, medication is not an optional add-on — it is life-saving, evidence-based care and is fully compatible with mental health treatment. The medications for opioid use disorder (MOUD) are well studied and effective:

• Buprenorphine — a partial opioid agonist that reduces cravings and withdrawal; can be prescribed in office-based settings.
• Methadone — a full agonist dispensed through opioid treatment programs, with the strongest evidence base for retention.
• Naltrexone — an opioid antagonist (including a long-acting injectable form) that blocks opioid effects.

Naloxone (Narcan) reverses opioid overdose and should be offered widely — to clients, families, and anyone likely to witness an overdose. Distributing naloxone and teaching its use is a core harm reduction and safety intervention.

New Hampshire has been hit especially hard by the opioid and fentanyl crisis, with among the highest overdose death rates in the country during the peak years. The state's response centers on a hub-and-spoke access model known as the Doorway.

For clinicians, the practical work is coordination: linking clients between community mental health centers and SUD providers, warm-handing off to a Doorway when specialized addiction services are needed, and building relationships with peer recovery supports so that integrated care extends across the systems a client actually touches. Knowing the local Doorway and referral pathways turns an abstract standard of care into something a client can reach this week.

Meridian's verified directory includes New Hampshire providers, community mental health centers, and substance use treatment programs, many of whom offer integrated care for co-occurring disorders.